ReShape Lifesciences Inc. (RSLS)
NASDAQ: RSLS · Real-Time Price · USD
0.3650
-0.0150 (-3.95%)
At close: Apr 25, 2025, 4:00 PM
0.3614
-0.0036 (-0.99%)
After-hours: Apr 25, 2025, 7:27 PM EDT

ReShape Lifesciences Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for ReShape Lifesciences.

Analyst Consensus: Hold
Target Low Average Median High
Price n/a n/a n/a n/a
Change n/a n/a n/a n/a

Analyst Ratings

According to 1 stock analyst, the rating for ReShape Lifesciences is "Hold". This means that the analyst believes this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating Jan '25Feb '25Mar '25Apr '25
Strong Buy 0000
Buy 0000
Hold 1111
Sell 0000
Strong Sell 0000
Total 1111

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Maxim Group
Maxim Group
Hold
Downgrades
n/a
Hold Downgrades n/a n/a Jul 17, 2024
Alliance Global Partners
Alliance Global Partners
Strong Buy
Maintains
$15,950$13,485
Strong Buy Maintains $15,950$13,485 +3,694,420.55% May 26, 2022
Maxim Group
Maxim Group
Strong Buy
Initiates
$23,200
Strong Buy Initiates $23,200 +6,356,064.38% Oct 8, 2021
More Analyst Ratings

Financial Forecast

Revenue This Year
12.23M
from 8.01M
Increased by 52.80%
Revenue Next Year
n/a
from 12.23M
EPS This Year
-0.37
from -13.83
EPS Next Year
n/a
from -0.37
Fiscal Year FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Period Ending Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025
Revenue
11.30M13.60M11.24M8.68M8.01M12.23M
Revenue Growth
-25.12%20.37%-17.35%-22.79%-7.74%52.80%
EPS
----110.87-13.83-0.37
EPS Growth
------
Forward PE
------
No. Analysts
-----3
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 2025
High 12.6M
Avg 12.2M
Low 11.8M

Revenue Growth

Revenue Growth 2025
High
57.3%
Avg
52.8%
Low
46.8%

EPS Forecast

EPS 2025
High -0.38
Avg -0.37
Low -0.35

EPS Growth

EPS Growth 2025
High -
Avg -
Low -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.